Japanese pharma company Takeda's USD 62bn acquisition of London-listed Shire is expected to close soon. To gain approval from the European Commission (EC), Takeda has proposed to sell Shire's drug for inflammatory bowel disease (IBD), to avoid an overlap between the two companies. Mintoi Chessa-Florea talks to Yining Su about the proposed divestiture package and its likelihood of finding a buyer.